Floatz logo

PHOSPHONIC ACID, P-(2-(4-(6-AMINO-2-(((TRANS-4-(((3-(CYCLOHEXYLAMINO)PROPYL)AMINO)METHYL)CYCLOHEXYL)METHYL)AMINO)-4-PYRIMIDINYL)-1-PIPERAZINYL)ETHYL)-

Hodgkin Disease

GPCR Therapeutics, Inc.Small moleculePhase 2Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

150 Active assets in the Hodgkin Disease cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BBB
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
CARMUSTINE
VIVUS LLC
Phase 2BBB
Cytosin-Arabinosid
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB

View all 50 →

Same molecule, other indications

PHOSPHONIC ACID, P-(2-(4-(6-AMINO-2-(((TRANS-4-(((3-(CYCLOHEXYLAMINO)PROPYL)AMINO)METHYL)CYCLOHEXYL)METHYL)AMINO)-4-PYRIMIDINYL)-1-PIPERAZINYL)ETHYL)- is also rated in:

non-Hodgkin lymphomaDormant
B
Indicative ·
60 / 100
View asset →
plasma cell myelomaDormant
CCC
Indicative ·
55 / 100
View asset →
prostate cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →